Crescendo Biologics

45 articles with Crescendo Biologics

• Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

  11/5/2018

  Crescendo Biologics Ltd today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.

• 

  Takeda Licenses Oncology Target from Crescendo Biologics

  11/5/2018

  Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical  licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.

• Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

  10/18/2018

  Crescendo Biologics Ltd today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer.

• Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer

  9/12/2018

  Crescendo Biologics Ltd today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.

• Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda

  8/15/2018

  Crescendo Biologics Ltd announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE:4502).

• Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing

  4/30/2018

  Crescendo Biologics Ltd announced that it has completed a $70 million (€57 million) Series B financing.

• Crescendo Biologics Appoints Edward J. Stewart As Chief Business Officer

  6/14/2017

• Crescendo Biologics Appoints Philip Bland-Ward As Chief Scientific Officer

  4/4/2017

• Genedata AG Release: Pharma Partners With Crescendo Biologics On Next-Generation Immuno-Oncology And ADC Programs

  1/10/2017

• Crescendo Biologics Appoints Theodora Harold As Chief Financial Officer

  10/20/2016

• Tiny Crescendo Biologics Hammers Out $790 Million Immuno-Oncology Deal With Biotech Giant Takeda

  10/11/2016

• Crescendo Biologics Strengthens IP Portfolio With U.S. Patent To Transgenic Mouse Platform For Generating Humabody Therapeutics

  9/28/2016

• Crescendo Biologics Appoints Dr Barbara Fleck As Head Of Intellectual Property

  2/2/2016

• Crescendo Biologics Appoints Dr Kevin Johnson As Chairman

  11/17/2015

• Crescendo Biologics Expands ADC Programmes With Innovate UK Funding Award

  5/28/2015

• Crescendo Biologics To Present At Biotech Showcase™ 2015

  1/6/2015

• Crescendo Biologics' Receives Further Investment From Astellas Venture Management To Develop Novel Humabody Therapeutics Targeting Immune Checkpoint Inhibitors

  12/16/2014

• EMBL Ventures Invests £2M ($3.3M) In A Second Close Of Crescendo Biologics' Series A Financing

  4/3/2014

• Crescendo Biologics Nabs $28 Million In Series A Financing

  12/17/2013

• Crescendo Biologics Announces the Crescendo Mouse

  1/16/2013